Rentschler brings single-use system online

By Gareth Macdonald contact

- Last updated on GMT

Rentschler  brings single-use system online
Rentschler brings single-use system online

Related tags: Biotechnology

Rentschler Biotechnologie has increased single-use bioreactor capacity at its manufacturing site in Laupheim, Germany and is moving forward with plans to invest €25m ($27m) in a new stainless steel system in the next few months.

The contract manufacturing organisation (CMO) announced it had installed a 2,000L single-use reactor at the site this week, explaining that the investment was prompted by growing customer demand for this type of production.

Spokesman Marion Schrader told us: “We see an increasing need for production capacity in the mid-scale. The expansion will allow us to match the growing demands of our clients for all clinical phases and even for market supply and will increase our flexibility."

Schrader said Rentschler had opted for a single-use bioreactor system manufacturered by GE Healthcare’s Xcellerex unit, adding that the CMO works with a diverse range of mammalian cell lines.

We are focused on the development and manufacturing of therapeutic proteins such as monoclonal antibodies, fusion proteins, cytokines or enzymes.​"

Biopharma customers

The single-use reactor becomes operational just a year after Rentschler expanded its biomanufacturing customer base, notably adding Apeiron’s neuroblastoma candidate monoclonal antibody (mAb) APN311​ to its list of production contracts.

The German CMO replaced a previous unnamed contractor.

Rentschler has also committed €24m to install two 3,000 litre stainless steel bioreactors at the facility. The project, which was announced last July, is designed to up the CMO’s cell culture-based protein production capacity.

The steel bioreactors are expected to become operational in 2017.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars